


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert L. Cafferata  
Serial No.: Not Yet Assigned  
Filed: Herewith  
For: SYSTEMS AND METHODS FOR TREATING ISCHEMIA  
Examiner: Jacqueline F. Stephens  
Art Unit: 3761

Express Mail mailing label number EV340040289 US Date of Deposit: January 29, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: MAIL STOP PATENT APPLICATION, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

John F. Perullo  
(Typed or printed name of person mailing paper or fee)

  
(Signature of person mailing paper or fee)

MAIL STOP PATENT APPLICATION  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 C.F.R. §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the applicants request consideration of this information disclosure statement.

**Compliance with 37 C.F.R. §1.97**

This information disclosure statement has been filed within three months of the filing date of a national application. No fee or certification is required.

**Compliance with 37 C.F.R. §1.98(d)**

This application is a continuation of application Serial No. 09/159,834 filed September 24, 1998. Information listed on the attached PTO 1449 form and marked with an asterisk (\*) indicates information that was also cited in the parent application in compliance with 37 C.F.R. §1.98(a)-(c). Copies of these references have not been resubmitted with this filing.

**Information Cited**

The applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the relative importance of the references.

**Explanation of Non-English Language References and  
Remarks Concerning Other Information Cited**

The following is a concise explanation of the relevance of each non-English language reference listed on the attached form PTO-1449 (modified):

**DE 19703482, and DE 29619029U1** are German language documents. An English language Derwent abstract for each was provided with the parent application.

**FR 1,514,319, and FR 1,278,965** are French language documents. Due to the age of the documents, an English language abstract was not available from the Derwent World Patent Index database. For **FR 2,725,615**, an English language Derwent abstract for each was provided with the parent application.

**RU 2026640 C1 and RU 2063179** are Russian language documents. An English language Derwent abstract for each was provided with the parent application.

**Remarks**

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

- The examiner consider completely the cited information, along with any

other information, in reaching a determination concerning the patentability of the present claims;

- The enclosed form PTO-1449 be signed by the examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
- The citations for the information be printed on any patent which issues from this application.


By submitting this information disclosure statement, the applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this information disclosure statement, the applicant makes no representation that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this information disclosure statement, the applicant makes no representation that the information cited in the statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

It is understood by applicant that the foregoing information will be considered and, to the extent deemed appropriate by the examiner, will be reflected in the examiner's communication.

Respectfully submitted,



John F. Perullo  
Reg. No. 39,498  
Kirkpatrick & Lockhart LLP  
75 State Street  
Boston, Massachusetts 02109  
Customer No.: 022832  
Tel: (617) 261-3100  
Attorneys for Applicant

Docket No.: B0410/7273D1

Date: January 29, 2004

Form PTO-1449 INFORMATION DISCLOSURE STATEMENT	Docket No.: B0410/7273D1	Serial No.: Not Yet Assigned
	Applicant: Robert L. Cafferata et al.	
	Filed: Herewith	Group: 3761

U.S. Patent Documents							
Ex.		Doc. No.	Date	Name	Class	Subcl.	Filed
	*	6,458,092	10/2002	Gambale et al.			
	*	6,447,522	09/2002	Gambale et al.			
	*	6,432,126	08/2002	Gambale et al.			
	*	6,263,880	07/2001	Parker et al.			
	*	6,251,418	06/2001	Ahern et al.			
	*	6,248,112	06/2001	Gambale et al.			
	*	6,227,082	08/2001	Gambale			
	*	6,197,324	03/2001	Crittenden			
	*	6,045,565	04/2000	Ellis et al.			
	*	5,980,548	11/1999	Evans et al.			
	*	5,971,993	10/1999	Hussein et al.			
	*	5,899,915	05/1999	Saadat			
	*	5,879,383	03/1999	Bruchman et al.			
	*	5,861,032	01/1999	Subramaniam			
	*	5,840,059	11/1998	March et al.			
	*	5,833,608	11/1998	Ellis Acker			
	*	5,830,502	11/1998	Dong et al.			
	*	5,824,071	10/1998	Nelson et al.			
	*	5,824,049	10/1998	Ragheb et al.			
	*	5,817,101	10/1998	Fiedler			
	*	5,810,836	09/1998	Hussein et al.			
	*	5,807,384	09/1998	Mueller			
	*	5,797,870	08/1998	March et al.			
	*	5,792,453	08/1998	Hammond et al.			
	*	5,785,702	07/1998	Murphy et al.			
	*	5,782,823	07/1998	Mueller			
	*	5,769,843	06/1998	Abela et al.			
	*	5,756,127	05/1998	Grisoni et al.			
	*	5,755,682	05/1998	Knudson et al.			
	*	5,744,515	04/1998	Clapper			
	*	5,741,330	04/1998	Brauker et al.			
	*	5,735,897	04/1998	Buirge			
	*	5,690,643	11/1997	Bandular-Wijay			
	*	5,682,906	11/1997	Sterman et al.			
	*	5,676,850	10/1997	Reed et al.			
	*	5,666,970	09/1997	Smith			
	*	5,662,124	09/1997	Wilk			
	*	5,656,029	08/1997	Imran et al.			
	*	5,655,548	08/1997	Nelson et al.			
	*	5,653,756	08/1997	Clarke et al.			
	*	5,643,308	07/1997	Markman			

U.S. Patent Documents							
Ex.		Doc. No.	Date	Name	Class	Subcl.	Filed
	*	5,629,008	05/1997	Lee			
	*	5,614,206	03/1997	Randolph et al.			
	*	5,602,301	02/1997	Field			
	*	5,593,434	01/1997	Williams			
	*	5,593,412	01/1997	Martinez et al.			
	*	5,571,168	11/1996	Toro			
	*	5,569,272	10/1996	Reed			
	*	5,562,922	10/1996	Lambert			
	*	5,562,619	10/1996	Mirarchi et al.			
	*	5,562,613	10/1996	Kaldany			
	*	5,558,091	09/1996	Acker et al.			
	*	5,551,954	09/1996	Buscemi et al.			
	*	5,551,427	09/1996	Altman			
	*	5,514,176	05/1996	Bosley, Jr. et al.			
	*	5,501,664	03/1996	Kaldany			
	*	5,487,739	01/1996	Aebischer et al.			
	*	5,480,422	01/1996	Ben-Halm			
	*	5,476,505	12/1995	Limon			
	*	5,466,242	11/1995	Mori			
	*	5,464,650	11/1995	Berg et al.			
	*	5,464,404	11/1995	Abela et al.			
	*	5,458,615	10/1995	Klemm			
	*	5,453,090	09/1995	Martinez et al.			
	*	5,452,733	09/1995	Sterman			
	*	5,441,516	11/1995	Wang et al.			
	*	5,429,144	06/1995	Wilk			
	*	5,425,757	01/1995	Tiefenbrun et al.			
	*	5,423,885	06/1995	Williams			
	*	5,409,019	04/1995	Wilk			
	*	5,409,004	04/1995	Sloan			
	*	5,405,376	04/1995	Mulier et al.			
	*	5,391,199	02/1995	Ben-Haim			
	*	5,389,096	02/1995	Alta et al.			
	*	5,386,828	02/1995	Owens et al.			
	*	5,380,316	01/1995	Alta et al.			
	*	5,372,600	12/1994	Beyar et al.			
	*	5,366,493	11/1994	Scheiner et al.			
	*	5,328,470	07/1994	Nabel et al.			
	*	5,324,325	06/1994	Moaddeb			
	*	5,312,456	05/1994	Reed et al.			
	*	5,290,295	03/1994	Querals et al.			
	*	5,287,861	02/1994	Wilk			
	*	5,269,326	12/1993	Verrier			
	*	5,266,073	11/1993	Wall			
	*	5,256,146	10/1993	Ensminger et al.			
	*	5,190,058	03/1993	Jones et al.			
	*	5,180,366	01/1993	Woods			
	*	5,176,626	01/1993	Soehendra			

U.S. Patent Documents							
Ex.		Doc. No.	Date	Name	Class	Subcl.	Filed
	*	5,172,699	12/1992	Svenson			
	*	5,167,614	12/1992	Tessman et al.			
	*	5,158,548	10/1992	Lau et al.			
	*	5,114,414	05/1992	Buchbinder			
	*	5,098,374	03/1992	Othel-Jacobsen et al.			
	*	5,087,243	02/1992	Avitall			
	*	5,056,517	10/1991	Fenici			
	*	5,049,138	09/1991	Chevalier et al.			
	*	5,047,028	09/1991	Gian			
	*	5,042,486	08/1991	Pfeiler et al.			
	*	5,040,543	08/1991	Badera et al.			
	*	4,997,431	03/1991	Isner et al.			
	*	4,995,857	02/1991	Arnold			
	*	4,950,227	08/1990	Savin et al.			
	*	4,920,980	05/1990	Jackowski			
	*	4,917,666	04/1990	Solar et al.			
	*	4,894,057	01/1990	Howes			
	*	4,889,137	12/1989	Kolobow			
	*	4,861,330	08/1989	Voss			
	*	4,852,580	08/1989	Wood			
	*	4,813,925	03/1989	Anderson, Jr. et al.			
	*	4,791,939	12/1998	Maillard			
	*	4,785,815	11/1988	Cohen			
	*	4,774,949	10/1988	Fogarty			
	*	4,768,507	09/1988	Fischell et al.			
	*	4,733,665	03/1988	Palmaz			
	*	4,718,425	01/1988	Tamaka et al.			
	*	4,700,692	10/1987	Baumgartner			
	*	4,681,110	07/1987	Wiktor et al.			
	*	4,665,918	05/1987	Garza et al.			
	*	4,658,817	04/1987	Hardy et al.			
	*	4,655,771	04/1987	Wallsten			
	*	4,649,922	03/1987	Wiktor			
	*	4,641,653	02/1987	Rockey			
	*	4,582,181	04/1986	Samson			
	*	4,580,568	04/1986	Gianturco			
	*	4,562,597	01/1986	Possis et al.			
	*	4,546,499	10/1985	Possis			
	*	4,503,569	03/1985	Dotter			
	*	4,451,253	05/1984	Harman			
	*	4,461,280	07/1984	Baumgartner			
	*	4,307,722	12/1981	Evans et al.			
	*	3,995,617	12/1976	Watkins et al.			
	*	3,991,750	11/1976	Vickery			
	*	3,680,544	08/1972	Shinnick et al.			

U.S. Patent Application Documents							
Ex.		Serial No.	Filed	Name	Class	Subcl.	Filed
	*	10/048,694	06/2002	Gambale et al.			
	*	10/048,205	05/2002	Gambale			
	*	09/990,644	11/2001	Gambale et al.			
	*	09/888,757	06/2001	Ahern et al.			
	*	09/774,320	01/2001	Gambale et al.			
	*	09/774,319	01/2001	Gambale et al.			
	*	09/743,726	04/2001	Gambale et al.			
	*	09/743,695	04/2001	Weiser et al.			
	*	09/368,119	08/1999	Tedeschi et al.			
	*	09/328,808	06/1999	Ahern			
	*	09/299,795	04/1999	Ahern			
	*	09/211,332	12/1998	Gambale			
	*	09/162,547	09/1998	Gambale			
	*	09/159,834	09/1998	Cafferata			
	*	09/073,118	05/1998	Gambale			

FOREIGN PATENT DOCUMENTS							
Ex.		Doc. No.	Date	Name	Class	Subcl.	
	*	DE 29619029U1	04/1997	Kletka			
	*	DE 19703482	01/1997	Dotter			
	*	EP 0953320 A2	11/1999	Tuch			
	*	EP 0853921 A2	07/1998	Harman et al.			
	*	EP 0830873 A2	03/1998	Ogawa et al.			
	*	EP 0812574 A2	12/1997	Mueller et al.			
	*	EP 0207438	01/1997	Germain			
	*	EP 0732089 A2	09/1996	Anderson et al.			
	*	EP 0717969 A2	06/1996	Sepetka et al.			
	*	EP 0714640 A1	06/1996	Stack et al.			
	*	EP 0515867 A2	12/1992	Jeevanandam et al.			
	*	EP 0490459A1	06/1992	Gross			
	*	EP 0363661	04/1990	Miller et al.			
	*	EP 0132387	01/1985	Osborne			
	*	FR 2725615	10/1994	De La Caffiniere			
	*	FR 1514319	01/1967	Zacouto			
	*	FR 1278965	01/1961	Van Steenbrugghe et al.			
	*	WO 99/55252	11/1999	Vacanti			
	*	WO 99/53863	10/1999	Vanney et al.			
	*	WO 99/38459	08/1999	Wilk			
	*	WO 99/21510	05/1999	Evans			
	*	WO 98/46115	10/1998	Makower			
	*	WO 98/29148	07/1998	Yang et al.			
	*	WO 98/32859	07/1998	Rosengart et al.			
	*	WO 98/23228	06/1998	Burkoth et al.			
	*	WO 98/25533	06/1998	Hektner			
	*	WO 98/16644	04/1998	Deisher et al.			

FOREIGN PATENT DOCUMENTS							
Ex.		Doc. No.	Date	Name	Class	Subcl.	
	*	WO 98/08456	03/1998	Makower et al.			
	*	WO 98/05307	02/1998	Kaplan et al.			
	*	WO 97/45105	12/1997	Hunter et al.			
	*	WO 97/47253	12/1997	Fine			
	*	WO 97/44071	11/1997	Sudai			
	*	WO 97/42910	11/1997	Danadio			
	*	WO 97/38730	10/1997	Bertrand et al.			
	*	WO 97/32551	09/1997	Hussein et al.			
	*	WO 97/16169	05/1997	Hung			
	*	WO 96/39830	12/1996	March et al.			
	*	WO 94/40368	12/1996	Igo et al.			
	*	WO 96/20698	07/1996	Levy et al.			
	*	WO 95/33511	12/1995	Lee			
	*	WO 94/27612	12/1994	French et al.			
	*	WO 94/05265	03/1994	Berde et al.			
	*	WO 91/15254	10/1991	Zimmon			
	*	WO 90/06723	06/1990	Rose et al.			
	*	WO 89/01798	03/1989	Jacobsen			
	*	RU 2026640 C1	01/1995	Kononov			
	*	RU 2063179 C1	07/1996	Ganichev			

OTHER DOCUMENTS (including, Author, Title, Date, Pages, Etc.)		
	*	Abela et al., "Laser revascularization: where are its prospects?" <i>Journal of Cardiovascular Medicine</i> 977-984 (09/1983)
	*	Abela et al., "Use of laser radiation to recanalize totally obstructed coronary arteries" (Abstract) <i>Journal American College Cardiology</i> 1:691 (1983)
	*	<i>Abstracts from the 70<sup>th</sup> Scientific Sessions</i> , Orange County Convention Center, Orlando, Florida, Nov. 9-12, 1997, Supplement to <i>Circulation</i> 96(8) (10/1997)
	*	Anabtawi et al., "Experimental evaluation of myocardial tunnelization as a method of myocardial revascularization" <i>Journal of Thoracic and Cardiovascular Surgery</i> 58:638-646 (1969)
	*	Aoki et al., "Survival of grafts of genetically modified cardiac myocytes transfected with FITC-labeled oligodeoxynucleotides and the galactosidase gene in the noninfarcted area, but not the myocardial infarcted area" <i>Gene Therapy</i> 4:120-127 (1997)
	*	Arras et al., "The delivery of angiogenic factors to the heart by microsphere therapy" <i>Nature Biotechnology</i> 16:159-162 (02/1998)
	*	Braun, "MYF-5 and MYOD genes are activated in distinct mesenchymal stem cells and determine different skeletal muscle cell lineages" <i>EMBO J.</i> 15:310-318 (01/1996)
	*	Burhenne, "Less invasive medicine: historical perspectives" <i>Boston Scientific Online</i> , <a href="http://www.bsci.com/corporate/specialreport1.html">www.bsci.com/corporate/specialreport1.html</a> ; pp:1-8 (5/20/99)
	*	Butler, "Evidence for a regenerative capacity in adult mammalian cardiac myocytes" <i>Am. J. Physiol.</i> 256:R797-R800 (03/1989)
	*	Chiu et al., "Cellular cardiomyoplasty: myocardial regeneration with satellite cell implantation" <i>Ann. Thorac. Surg.</i> 60:12-18 (07/1995)
	*	Doiter, "Transluminally-placed coilsping endarterial tube grafts" <i>Investigative Radiology</i> 4:329-332 (09-10/1969)



OTHER DOCUMENTS (including, Author, Title, Date, Pages, Etc.)		
	*	Ferrari, "Muscle regeneration by bone marrow-derived myogenic progenitors" <i>Science</i> 279:1528-1530 (03/1998)
	*	Folkman et al., "Blood vessel formation: what is its molecular basis?" <i>Cell</i> 87:1153-1155 (12/1996)
	*	Folkman, "Angiogenic therapy for the human heart" <i>Amer. Heart Assoc. Editorial, Circulation</i> 97:628-629 (1998)
	*	Gibbons et al., "Molecular therapies for vascular disease" <i>Science</i> 272:689-693 (05/1996)
	*	Gojo et al., "Ex vivo gene transfer into myocardium using replication-defective retrovirus" <i>Cell Transportation</i> 5:S81-S84 (1996)
	*	Gojo et al., "Transplantation of genetically marked cardiac muscle cells" <i>J. Thorac. Cardiovasc. Surg.</i> 113:10-18 (1997)
	*	Goldman et al., "Experimental methods for producing a collateral circulation to the heart directly from the left ventricle" <i>Journal of Thoracic Surgery</i> 31:364-374 (03/1956)
	*	Gulati, "Regeneration pattern of cardiac and skeletal muscle after transplantation into a skeletal muscle bed in rats" <i>Anat. Rev.</i> 242:188-194 (06/1995)
	*	Hardy et al., "Regional myocardial blood flow and cardiac mechanics in dog hearts with CO <sub>2</sub> laser-induced intramyocardial revascularization" <i>Basic Research Cardiology</i> 85:179-197 (1990)
	*	Hershey et al., "Transmyocardial puncture revascularization" <i>Geriatrics</i> 24:101-108 (03/1969)
	*	Heschler et al., "Embryonic stem cells: a model to study structural and functional properties in cardiomyogenesis" <i>Cardiovascular Research</i> 16:149-162 (1997)
	*	Ingels et al., "Measurement of midwall myocardial dynamics in intact man by radiography of surgically implanted markers" <i>Circulation</i> 52:859-867 (11/1975)
	*	Innovative Research of America, "Time release pellets for biomedical research" 2000 <i>Catalog, Innovative Research of America</i> , 2 Tamiami Trail, Suite 404, Sarasota, Florida 34236
	*	Jeevanandam et al., "Myocardial revascularization by laser-induced channels" <i>Cardiothoracic Surg. XLI</i> :225-227 (10/1990)
	*	Jia et al., "Transplanted cardiomyocytes survive in scar tissue and improve heart function" <i>Transplantation Proceedings</i> 29:2093-2094 (1997)
	*	Khazei et al., "Myocardial canalization: a new method of myocardial revascularization" <i>The Annals of Thoracic Surgery</i> 6:163-171 (08/1968)
	*	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth <i>in vivo</i> " <i>Nature</i> 362:841-844 (1993)
	*	Knighton et al., "Wound healing angiogenesis: indirect stimulation by basic fibroblast growth factor" <i>The Journal of Trauma</i> 30:S134-S144 (1990)
	*	Kuzela et al., "Experimental evaluation of direct transventricular revascularization" <i>Journal of Thoracic and Cardiovascular Surgery</i> 57:770-773 (06/1969)
	*	Lee et al., "Feasibility of intravascular laser irradiation for <i>in vivo</i> visualization and therapy of cardiocirculatory diseases" <i>American Heart Journal</i> 103:1076-1077 (06/1982)
	*	Lee et al., "Laser-dissolution of coronary atherosclerotic obstruction" <i>American Heart Journal</i> 102:1074-1075 (12/1981)
	*	Li et al., "Cardiomyocyte transplantation improves heart function" <i>Ann. Thorac. Surg.</i> 62:654-661 (1996)
	*	Li et al., "Cell therapy to repair broken hearts" <i>Can. J. Cardiology</i> 14:735-744 (1998)

OTHER DOCUMENTS (including, Author, Title, Date, Pages, Etc.)		
	*	Li et al., "Natural history of fetal rat myocytes transplanted into adult rat myocardial scar tissue" <i>Circulation</i> 96:II-179—II-187 (1997)
	*	Lincoff et al., "Local drug delivery for the prevention of restenosis: fact, fancy and future" <i>Circulation</i> 90:2070-2084 (10/1994)
	*	Maciag, "Molecular and cellular mechanisms of angiogenesis" <i>Important Adv. Oncol.</i> pp. 85-98 (1990)
	*	Makino et al., "Establishment of a cardiomyogenic cell line from mouse bone marrow stomal cell exposed to 5-azacytidine" <i>Abstracts from the 70<sup>th</sup> Scientific Sessions</i> , Orange County Convention Center, Orlando, Florida, Nov. 9-12, 1997, Supplement to <i>Circulation</i> 96(8) (10/1997)
	*	Martinelli et al., "Intraluminal ultrasound guidance of transverse laser coronary atherectomy" <i>Optical Fibers in Medicine</i> 1201:68-78 (1990)
	*	Massimo et al., "Myocardial revascularization by a new method of carrying blood directly from the left ventricular cavity into the coronary circulation" <i>Journal of Thoracic Surgery</i> 34:257-264 (08/1957)
	*	McKay, "Catheter-based techniques of local drug delivery" <i>The New Manual of Interventional Cardiology</i> pp. 645-660 (1996)
	*	Mima et al., "Fibroblast growth factor receptor is required for <i>in vivo</i> cardiac myocyte proliferation at early embryonic stages of heart development" <i>Proc. Natl. Acad. Sci. USA</i> 92:467-471 (01/1995)
	*	Mirhoseini et al., "Clinical report: laser myocardial revascularization" <i>Lasers in Surgery and Medicine</i> 6:459-461 (1986)
	*	Mirhoseini et al., "Myocardial Revascularization by laser: a clinical report" <i>Lasers in Surgery and Medicine</i> 3:241-245 (1983)
	*	Mirhoseini et al., "New concepts in revascularization of the myocardium" <i>The Annals of Throacic Surgery</i> 45:415-450 (04/1988)
	*	Mirhoseini et al., "Revascularization of the heart by laser" <i>Journal of Microsurgery</i> 2:253-260 (06/1981)
	*	Mirhoseini et al., "Transventricular revascularization by laser" <i>Lasers in Surgery and Medicine</i> 2:187-198 (1982)
	*	Murry et al., "Muscle differentiation during repair of myocardial necrosis in rats via gene transfer with MYOD" <i>The American Society for Clinical Investigation, Inc.</i> 98:2209-2217 (11/1996)
	*	Murry et al., "Skeletal myoblast transplantation for repair of myocardial necrosis" <i>The American Society of Clinical Investigation, Inc.</i> 98:2512-2523 (12/1996)
	*	Olwin et al., "Are fibroblast growth factors regulators of myogenesis <i>in vivo</i> ?" <i>Progress in Growth Factor Research</i> 5:145-158 (1994)
	*	Parker et al., "Growth factors, proto-oncogenes, and plasticity of the cardiac phenotype" <i>Ann. Rev. Physiol.</i> 53:179-200 (1991)
	*	Penisi, "Bone marrow cells may provide muscle power" <i>Science</i> 279:1456 (03/1998)
	*	Piffare et al., "Myocardial revascularization by transmymocardial acupuncture: a physiologic impossibility" <i>Journal of Thoracic and Cardiovascular Surgery</i> 58:424-429 (09/1969)
	*	Ranade, "Drug delivery systems: 3A. Role of polymers in drug delivery" <i>J. Clin. Pharmacol.</i> 30:10-23 (1990)
	*	Riessen et al., "Prospects for site-specific delivery of pharmacologic and molecular therapies" <i>JACC</i> 23:1234-1244 (04/1994)
	*	Robinson et al., "Implantation of skeletal myoblast-derived cells" <i>Cellular Cardiomyoplasty: Myocardial Repair with Cell Implantation</i> , R.G. Landes Co., 79-104 (1997)

OTHER DOCUMENTS (including, Author, Title, Date, Pages, Etc.)		
	*	Robinson, "Arterial delivery of genetically labeled skeletal myoblasts to the murine heart: long-term survival and phenotypic modification of implanted myoblasts" <i>Cell Transplantation</i> 5:77-91 (1996)
	*	Sachinopoulou et al., "Invited review transmyocardial revascularization" <i>Lasers in Medical Science</i> 10:83-91 (09/1995)
	*	Schumacher et al., "Induction of neoangiogenesis in ischemic myocardium by human growth factors, first clinical results of a new treatment of coronary heart disease" <i>Circulation</i> 97:645-650 (12/1997)
	*	Sen et al., "Further studies in multiple transmyocardial acupuncture as a method of myocardial revascularization" <i>Surgery</i> 64:861-870 (11/1968)
	*	Sen et al., "Transmyocardial acupuncture: a new approach to myocardial revascularization" <i>Journal of Thoracic and Cardiovascular Surgery</i> 50:181-189 (1965)
	*	Smith, "Adult rat cardiomyocyte proliferation assay" <i>In Vitro Cell Biol.</i> 33:428-431 (06/1997)
	*	Tam et al., "Cardiac myocyte terminal differentiation, potential for cardiac regeneration" <i>Ann. NY Acad. Sci.</i> 275:72-79 (03/1995)
	*	Ueno et al., "Adenovirus-mediated expression of the secreted form of basic fibroblast growth factor (FGF02) induces cellular proliferation and angiogenesis <i>in vivo</i> " <i>Arterioscler. Throm. Vasc. Biol.</i> 17:2453-2460 (1997)
	*	Wakitani et al., "Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine" <i>Muscle Nerve</i> 18:1417-1426 (12/1995)
	*	Waller, "Anatomy, histology, and pathology of the major epicardial coronary arteries relevant to echocardiographic imaging techniques" <i>J. Amer. Soc. Echocardiography</i> 2:232-252 (1989)
	*	Walter et al., "Treatment of acute myocardial infarction by transmural blood supply from the ventricular cavity" <i>Europ. Surg. Res.</i> 3:130-138 (1971)
	*	Warejcka et al., "A population of cells isolated from rat heart capable of differentiating into several mesodermal phenotypes" <i>J. Surg. Res.</i> 62:233-242 (1996)
	*	Whittaker et al., "Transmural channels can protect ischemic tissue, assessment of long-term myocardial response to laser and needle-made channels" <i>Circulation</i> 93:143-152 (01/1996)
	*	Wilensky et al., "Methods and devices for local drug delivery in coronary and peripheral arteries" <i>TCM</i> 3:163-170 (1993)
	*	Yamaguchi, "Regulation of differentiation pathway of skeletal mesenchymal cells in cell lines by transforming growth factor-beta superfamily" <i>Semin. Cell Biol.</i> 6:165-173 (06/1995)
	*	Zhai et al., "Inhibition of angiogenesis and breast cancer xenograft tumor growth by Vegf, a novel cytokine of the TNF superfamily" <i>Int. J. Cancer</i> 82:131-136 (07/1999)

Examiner:	Date considered
-----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. An \* indicates references that do not require a copy to be provided under 37 C.F.R. §1.98(d) because a copy was previously cited or submitted in a prior application, which is relied upon under 35 U.S.C. §120.